Researchers map the probiotic strains and gut-brain pathways being investigated across anxiety, depression, bipolar disorder, and schizophrenia, revealing a complex picture of how microbes may interact with mental health.

Psychobiotic Strategies for Managing Anxiety, Depression, and Schizophrenia: A Narrative Review. Image Credit: Lightspring / Shutterstock

In a recent narrative review published in the Journal of Restorative Medicine, researchers synthesized clinical and translational evidence on probiotic interventions, their proposed gut-brain mechanisms, and their potential effects across anxiety, depression, bipolar disorder, and schizophrenia.

Background

Mental illnesses can affect various aspects of our lives, such as mood, behavior, and thinking. But could our gut contribute to these experiences? The gut microbiome contains microorganisms that interact with the brain through the bidirectional gut-brain axis.

Changes in common gut microbes might be associated with specific psychiatric disorders. Psychobiotics are attracting increasing research and clinical interest, but further research is needed because studies differ in strains, doses, populations, durations, substrates, and outcome measures.

The gut-brain connection

The gut-brain axis provides a bidirectional communication pathway between the gastrointestinal tract and the central nervous system. Microbial metabolites, cytokines, neurotransmitters, and autonomic signals contribute to this communication.

Gut microorganisms are able to produce or change the synthesis of gamma-aminobutyric acid, serotonin, dopamine, acetylcholine, histamine, and norepinephrine. Lactobacillus and Bifidobacterium are linked with the production of gamma-aminobutyric acid, while several Lactobacillus species are capable of producing serotonin, acetylcholine, and histamine.

Microbial products may also stimulate the vagus nerve, thereby influencing hippocampal neurogenesis and neurotransmitter release in brain regions implicated in anxiety.

Tryptophan metabolism through the kynurenine, indole, and serotonin pathways can be influenced by gut microbes and their metabolites. Indole metabolites have been implicated in cognitive and mental functioning, behavior, and immunity. Short-chain fatty acids, particularly butyrate, can regulate tryptophan metabolism, while bacterial components such as lipopolysaccharides can stimulate immune-related pathways. Together, these pathways may connect gut microbial activity with brain signaling, inflammation, and stress responses.

Finally, the gut microbiome is important for maintaining the integrity of the intestinal barrier. Inflammatory cytokines such as interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha can influence the central nervous system and alter tryptophan metabolism. Alterations in the hypothalamic-pituitary-adrenal axis and cortisol levels provide another potential route connecting microbial changes with stress responses.

Anxiety and depression

Anxiety disorders involve excessive worry, fear, or anxiety. Conventional treatments include antidepressants, exposure therapy, cognitive behavioral therapy, lifestyle changes, and complementary strategies. Across studies, different probiotic strains were linked with improvements in anxiety-related outcomes. Bifidobacterium animalis subsp. lactis BB-12 was associated with improvements in cognitive state anxiety, somatic state anxiety, and anxiety emotion. Lactobacillus casei Shirota was associated with reduced salivary cortisol levels.

Lactobacillus plantarum DR7 reduced plasma cortisol, interferon-gamma, and tumor necrosis factor-alpha while increasing interleukin-10, and it enhanced attention, emotional cognition, and associative learning. Lactobacillus plantarum P-8 reduced stress- and anxiety-related symptoms. Lactobacillus rhamnosus HN001 mediated gamma-aminobutyric acid receptor expression and was associated with lower anxiety symptoms in postpartum women. NVP-1704, containing Lactobacillus reuteri NK33 and Bifidobacterium adolescentis NK98, reduced serum interleukin-6 and anxiety symptoms.

Major depressive disorder is characterized by persistent sadness, hopelessness, and loss of interest or pleasure that can impair functioning. Studies grouped by the review under depression linked Lactobacillus plantarum DR7 and P-8 with lower cortisol and inflammatory markers and psychological improvements. Lactobacillus casei Shirota was linked with lower salivary cortisol and plasma tryptophan and higher fecal serotonin. Lactobacillus reuteri NK33 and Bifidobacterium adolescentis NK98 were associated with reduced systemic inflammation and improvements in psychological symptoms.

Other studies grouped in the review’s depression table reported improvements in panic, negative affect, worry, mood regulation, training, and brain function. However, several studies summarized in this section involved populations experiencing stress, anxiety, postpartum symptoms, gastrointestinal symptoms, or athletic training rather than exclusively patients with diagnosed major depressive disorder.

Bipolar disorder and schizophrenia

Bipolar disorder involves episodes of mania or hypomania and depression that can impair social and occupational functioning. Schizophrenia involves positive, negative, and cognitive symptoms, which include hallucinations, delusions, disorganized thinking, reduced emotional expression, lack of motivation, social withdrawal, and difficulties with attention, memory, and executive functioning.

The reviewed evidence is emerging, particularly for psychotic disorders, while bipolar findings were more limited. Evidence in schizophrenia included Bifidobacterium breve A-1 at 10¹¹ CFU/day for four weeks, which was linked to reduced anxiety and depression and fewer negative symptoms.

A combination of Lactobacillus acidophilus, Bifidobacterium bifidum, Lactobacillus reuteri, and Lactobacillus fermentum administered with vitamin D was associated with improved Positive and Negative Syndrome Scale scores and changes in antioxidant, metabolic, and lipid-related measures.

For bipolar disorder, the review also cited probiotic trials in bipolar I disorder and acute mania, although the bipolar evidence base was comparatively limited.

Mechanisms, clinical relevance, and research gaps

Across conditions, proposed mechanisms include neurotransmitter modulation, immune regulation, reduced systemic inflammation, short-chain fatty acid production, improved gut barrier function, hypothalamic-pituitary-adrenal axis regulation, and hormonal modulation. However, short-chain fatty acids were not directly measured in most studies, making some mechanistic interpretations indirect.

Gamma-aminobutyric acid-mediated effects were particularly evident in anxiety, serotonergic modulation featured more strongly in depression, and schizophrenia findings were more closely associated with immune and inflammatory markers.

The review supports careful consideration of psychobiotics as adjuncts to conventional psychiatric care. Translation remains difficult because studies vary in participants, outcomes, treatment duration, strains, combinations, and doses.

Substrates and delivery methods are inconsistently controlled or reported, and many tested combinations differ from commercially available products. Postbiotics may offer more stable, targeted approaches. 

Future work should prioritize standardized protocols, validated dosing, transparent reporting, functional microbiome profiling, and long-term studies combining microbiome-based and conventional therapies.

Conclusions

The review concludes that psychobiotic interventions show potential as adjuncts across several psychiatric conditions, particularly anxiety, depression, and schizophrenia, with more limited evidence in bipolar disorder, through interconnected gut-brain mechanisms involving neurotransmitters, immune regulation, inflammation, short-chain fatty acids, gut barrier function, the hypothalamic-pituitary-adrenal axis, and cortisol.

Notable improvements in specific clinical outcomes have been linked to Lactobacillus and Bifidobacterium probiotic species, though results differ across disorders. Considerable differences between strains used in these studies and their methods limit clinical applicability and future identification of effective doses.

The review therefore emphasizes standardized protocols, validated dosing, functional microbiome profiling, and longitudinal research to evaluate safety, durability, and personalized applications within mental health care.